These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69. The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma. Parrish JK; Sechler M; Winn RA; Jedlicka P Oncogene; 2015 Jan; 34(2):257-62. PubMed ID: 24362521 [TBL] [Abstract][Full Text] [Related]
70. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma. Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018 [TBL] [Abstract][Full Text] [Related]
71. The role of menin in hematopoiesis. Maillard I; Hess JL Adv Exp Med Biol; 2009; 668():51-7. PubMed ID: 20175452 [TBL] [Abstract][Full Text] [Related]
72. Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis. Luo W; Xu C; Ayello J; Dela Cruz F; Rosenblum JM; Lessnick SL; Cairo MS Oncogene; 2018 Feb; 37(6):798-809. PubMed ID: 29059150 [TBL] [Abstract][Full Text] [Related]
73. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Fiskus W; Mill CP; Birdwell C; Davis JA; Das K; Boettcher S; Kadia TM; DiNardo CD; Takahashi K; Loghavi S; Soth MJ; Heffernan T; McGeehan GM; Ruan X; Su X; Vakoc CR; Daver N; Bhalla KN Blood Cancer J; 2023 Apr; 13(1):53. PubMed ID: 37055414 [TBL] [Abstract][Full Text] [Related]
74. C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells. Gardiner JD; Abegglen LM; Huang X; Carter BE; Schackmann EA; Stucki M; Paxton CN; Lor Randall R; Amatruda JF; Putnam AR; Kovar H; Lessnick SL; Schiffman JD Oncotarget; 2017 Apr; 8(16):26013-26026. PubMed ID: 28148901 [TBL] [Abstract][Full Text] [Related]
75. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53. van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828 [TBL] [Abstract][Full Text] [Related]
76. Challenges and opportunities in targeting the menin-MLL interaction. Cierpicki T; Grembecka J Future Med Chem; 2014 Mar; 6(4):447-62. PubMed ID: 24635524 [TBL] [Abstract][Full Text] [Related]
77. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. Romo-Morales A; Aladowicz E; Blagg J; Gatz SA; Shipley JM Pediatr Blood Cancer; 2019 Sep; 66(9):e27888. PubMed ID: 31207107 [TBL] [Abstract][Full Text] [Related]
78. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082 [TBL] [Abstract][Full Text] [Related]
79. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. Kovar H Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919 [TBL] [Abstract][Full Text] [Related]
80. The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer. Zhao X; Fu J; Du J; Xu W Int J Biol Sci; 2020; 16(9):1495-1506. PubMed ID: 32226297 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]